Abstract: Disclosed are compositions for alleviation from adverse physical effects and symptoms of responsible alcohol consumption, and methods for manufacturing and/or administering the compositions. In some aspects, a composition to alleviate discomforting symptoms associated with responsible alcohol consumption includes various formulations of ginger root, L-Theanine, and/or caffeine, which may be derived from particular ingredient sources. In some embodiments, the composition(s) may optionally include salicin. In some embodiments, the composition(s) may optionally include a blend of particular vitamins, electrolytes, and/or salts.

Abstract: A detergent composition and a method of washing/cleaning urushiol at least partially, more typically substantially or completely off a surface of human skin or clothing. The detergent composition is typically a non-buffered composition that contains one or more C12 surfactants, typically at least a sodium lauroyl sarcosinate and the detergent composition is typically free of one or more of (1) any nonylphenol ethoxylate; (2) any pharmaceutically active drug or prodrug; (3) any salt in an amount that affects the functional characteristics of either of the solely C12 surfactants; (4) any salt in granular form; and/or (5) any ethoxylate that is a stand-alone ingredient.

Abstract: The invention relates to an antimicrobial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and an acid and/or silver-based compound, and also to a cosmetic, pharmaceutical or nutritional composition containing such a mixture. Application to caring for, making up and cleansing keratin materials; to preserving foods and to water treatment.

Abstract: In an embodiment, a method to enhance a non-surgical medical treatment, the method including applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment, where the applying is at least one of before, during, and after the non-surgical medical treatment, beginning the non-surgical medical treatment to the area of skin, and continuing the non-surgical medical treatment until the non-surgical medical treatment is completed. In some embodiments, the antifibrinolytic agent is tranexamic acid in an amount of about 20% (w/v). In some embodiments, the method further includes minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment. In an additional embodiment, the present disclosure relates to a composition to enhance a non-surgical medical treatment, the composition having an antifibrinolytic agent. In a further embodiment, the present disclosure relates to a kit having a carrier and an antifibrinolytic agent.

Abstract: A method of cleaning and disinfecting a surface comprises producing a diluted cleaning disinfectant solution from a concentrated cleaning disinfectant solution, and contacting the surface with the diluted solution. A concentrated cleaning disinfectant solution is stable at freezing temperatures and comprises antimicrobial acid, surface cleaning acid, solubilizing agent, hydrotrope, and surfactant. The antimicrobial acid comprises a synergistic combination of (i) salicylic acid, derivative of salicylic acid, or a combination thereof, and (ii) gluconic acid, derivative of salicylic acid, or a combination thereof. The surface cleaning acid comprises at least one acid selected from mineral acid, methane sulfonic acid, formic acid, or sulfonic acid having an alkyl group with no greater than three carbon atoms. The surfactant selected from anionic surfactant, non-ionic surfactant, or a mixture thereof.

Abstract: The present invention provides compositions and methods for promoting glycogen synthase activity and augmenting glycogen storage capability in muscle tissue and/or liver tissue in a mammal, relating to administration to the mammal of an effective amount of ?-aminoisobutyric acid (BAIBA), an analog or derivative thereof, or a pharmaceutically acceptable salt, ester, acid, polymer, analog or derivative thereof.

Abstract: The present disclosure is related to dietary supplements. For example, this disclosure relates to compositions that include, one or more agents that decrease the production of reactive oxygen species (ROS) responsible for oxidative stress, and/or decrease the concentration of ROS. In some embodiments, a composition as provided herein includes epicatechin present in an amount of about 0.1% to about 3% w/w of the composition; vitamin A acid present in an amount of about 1% to about 15% w/w of the composition; vitamin C present in an amount of about 10% to about 80% w/w of the composition; and, vitamin E present in an amount of about 5% to about 60% w/w of the composition. Such compositions are useful for improving oxidative stress by decreasing ROS concentration.

Abstract: The present invention relates to methods for treatment or prevention of disorders caused influenced by dysfunction of ? cells by administering to said patient a compound selected from the group consisting of GABAA receptor agonists. The invention further relates to in vitro methods for finding potentially useful pharmaceutical compounds.

Abstract: The present invention is directed towards natural colorants comprising a material selected from the group consisting of genipin, purified genipin, pre-genipin compounds, iridoid compounds, genipin deriviatives, a genipin-containing substance, and combinations of any thereof; and a primary amine containing compound. Processes of making natural colorants are further disclosed. Additionally, processes of producing a desired color of natural colorants are disclosed.

Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 are as defined as set forth in the specification, and the deuterium enrichment of any one or more of R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, and R13 is about 15% or more. The present disclosure also provides compounds having Formula I for use to treat or delay the progression of a lysosomal storage disorder or a neurodegenerative disease in a subject, provide neuroprotection in a subject having a lysosomal disorder, treat or prevent a migraine, and the symptoms associated therewith, in a subject, or improve mobility and/or cognitive function in a subject.

Abstract: The present disclosure provides for treating neurodegenerative diseases comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods of treating a cancer that overexpresses NQO1 comprising administering KP372-1. In some embodiments, KP372-1 is administered with a polymerase inhibitor.

Abstract: The subject invention provides compositions and methods for inhibiting the growth and/or proliferation of cancer cells. The subject invention also provides methods for treating cancer in a subject in need of such treatment by administering a composition described herein. The subject invention can be used to inhibit cancer cell growth by exposing the cells to a composition. The subject invention further provides cancer treatments that may be used in combination with surgery, chemotherapy, and/or radiation therapy.

Abstract: A system includes: a liquid formulation comprising an antipsychotic agent and an implantable infusion device. The implantable infusion device includes a reservoir, an outlet in communication with the reservoir, a drive mechanism configured to cause liquid formulation in the reservoir to be delivered to the outlet, and control electronics coupled to the drive mechanism. The control electronics are programmed with instructions that cause the liquid formulation to be delivered from the reservoir to the outlet at a flow rate of less than 500 microliters per hour for a period of time sufficient to reach a therapeutically effective steady state concentration in a subject's cerebrospinal fluid (CSF) if the liquid is delivered to a CSF-containing space of a subject.

Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising (a) one or more osmoprotectants, (b) one or more poloxamer comfort agents and (c) one or more polyol demulcents, wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.

Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

Abstract: The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.

Abstract: The present invention includes a method of treating a bone disease caused by a intracellular protein trafficking defect comprising: identifying a subject having the bone disease caused by the intracellular protein trafficking defect in a membrane bound transcription factor peptidase, site 1 (MBTPS1) gene; and providing the subject with an effective amount of a composition that bypasses or corrects a defect in MBTPS1 gene expression, gene splicing, or corrects protein trafficking defects in the endoplasmic reticulum and to the lysosome.

Abstract: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.

Abstract: A composition for use in protecting the breast tissue and significantly lowering the high risk for breast cancer development in women includes Ganoderma lucidum, Quercetine, Embilica officinalis, Indole 3 carbinol, Camellia sinensis, Allium sativum, Iodine, and Selenium.

Abstract: The present disclosure is directed to acetyl-leucine or a pharmaceutically acceptable salt thereof for use in improving cognitive function, mobility, or cognitive function and mobility in a subject, for example, in an elderly subject.

Abstract: Disclosed are gastroretentive, sustained-release tablet formulations comprising an active agent, such as pregabalin or a pharmaceutically acceptable form thereof, crospovidone, and a cationic copolymer based on dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate random copolymer.

Abstract: A detergent composition and a method of washing/cleaning urushiol at least partially, more typically substantially or completely off a surface of human skin or clothing. The detergent composition is typically a non-buffered composition that contains one or more C12 surfactants, typically at least a sodium lauroyl sarcosinate and the detergent composition is typically free of one or more of (1) any nonylphenol ethoxylate; (2) any pharmaceutically active drug or prodrug; (3) any salt in an amount that affects the functional characteristics of either of the solely C12 surfactants; (4) any salt in granular form; and/or (5) any ethoxylate that is a stand-alone ingredient.

Abstract: The present application relates to a pregabalin sustained release composition, comprising: (a) an active ingredient; (b) a matrix-forming agent; (c) a swelling agent; (d) a gelling agent; and optionally a filler. The pregabalin sustained release composition provided in the present application can rapidly swell in volume when exposed to aqueous medium until exceeding the dimeter of human gastric pyloric (13 mm). It thereby prolongs the gastric emptying time to increase the retention time of pregabalin in the stomach and enhances absorption of pregabalin in the small intestine and ascending colon. Moreover, the pregabalin sustained release composition provided herein achieves a sustained release for 24 h, which allows QD (once a day) administration, reduces administration number, and improves patient compliance.

Abstract: Compositions containing at least four kinds of amino acids selected from the group consisting of serine, aspartic acid, glutamic acid, glycine, alanine and proline as active ingredients are useful for improving joint function and skin function and have high safety and permit continued ingestion or administration.

Abstract: Pharmaceutical compositions including an active ingredient and a stabilizer, as well as methods of manufacture of the compositions, and methods of their use. The composition may include the active ingredient dispersed throughout a matrix of the stabilizer. In some embodiments, the active ingredient and the stabilizer are intimately mixed in a matrix formulation. In some embodiments, the active ingredient is selected from 4 amino-3-(4-chlorophenyl)butanoic acid) (“baclofen”) and its pharmaceutically acceptable salts.

Abstract: An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.

Abstract: The present invention provides a method of treating depression disease in a treatment resistant patient comprising administering to a mucosal membrane of a patient an effective amount of a pharmaceutically acceptable composition comprising an effective amount of ketamine or dextromethorphan, wherein the mucosal administration of the ketamine or dextromethorphan containing composition allows for the mucosal absorption of the composition eliminating the digestive tract of the patient for effecting a rapid acting antidepressant treatment of the treatment resistant patient. This method includes administering the composition to a patient's mucosal membrane of a respiratory tract, a genitourinary tract, an oral tract, or rectal tract of the patient. A pharmaceutically acceptable composition comprising ketamine or dextromethorphan and a vehicle is disclosed. A biomarker for identifying a depressive disease is set forth.

Abstract: Methods of treating tumors by administering compounds to a patient are provided. Compounds such as drugs, may be administered to the patient orally, by injection, intravenously, or topically, which then accumulate preferentially as compounds such as protoporphyrin IX (PpIX) in tumor cells. After such accumulation, compounds such as PpIX are then activated in various aspects to treat tumors cells, thereby treating cancer. Cancers such as glioblastoma may be treated.

Abstract: The present invention is directed to an ingestible athletic performance enhancement composition comprising l-menthol wherein the composition does not contain alcohol. The present invention further includes athletic performance enhancement compositions wherein the amount of l-menthol is between 0.01 to 0.5 weight percent of the composition. The invention also includes methods of improving athletic performance comprising the ingestion of a composition comprising l-menthol, wherein the amount of l-menthol is sufficient to induce a cooling sensation while maintaining palatability and minimizing side effects.

Abstract: This disclosure provides methods of using compositions comprising amino acid entities to reduce fat infiltration in muscle, particularly under conditions of muscle atrophy. The disclosure also provides methods for enhancing muscle function by reducing fat infiltration in the muscle comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: Coherent light (e.g., laser light) is emitted into a tissue sample through an optical fiber. The tissue sample diffuses the coherent light. Different blood flow quantities generate different coherent light interference patterns. An image of a coherent light interference pattern is captured with an image sensor coupled to an optical fiber. The speckle contrast of the image quantifies coherent light interference pattern. The speckle contrast is determined and is mapped to blood flow quantities using one or more data models. A quantity of blood flow is identified in a tissue sample at least partially based on the speckle contrast value of the captured image.

Abstract: The invention relates to the cosmetic use of an association of (i) at least one polyphenol selected from the monomers and oligomers of flavonoids extracted from vines, the derivatives thereof and the mixtures thereof, and (ii) at least two essential oils selected from peppermint, geranium, lemon balm, lemongrass, rosemary and lavender, for treating and/or preventing oily skin or skin with oily tendencies and/or aesthetic skin problems associated therewith. The invention also relates to a cosmetic method for treating oily skin, and to compositions containing the association. It also relates to the association of polyphenols and the mixture of essential oils for treating acne or skin with oily tendencies.

Abstract: A particulate form of dithiocarbamate-metal complex and at least one blood protein. The particulate form is obtained by a process having a sequential or simultaneous addition of individual components, resulting in their self-assembling. The aqueous dispersion of the particulate form is suitable for parenteral, oral and topical administration and for therapy and visualization of cancer.

Abstract: Application of valine in the preparation of a medicine for treating or preventing avian influenza virus infection. In a lethal mouse influenza infection model, the use of valine to treat infected mice can effectively improve the weight loss of mice, increase the survival rate of mice, and can effectively reduce the virus titer in the supernatant of the lung tissue of the infected mice.

Abstract: The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.

Abstract: A photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient is disclosed herein. In one embodiment, a treatment laser is applied to a body portion of a patient using a painting technique, the treatment laser being configured to provide paint brush-type photodynamic therapy (PPDT) using the painting technique to the body portion of the patient by emitting light of a predetermined wavelength that is absorbed by tissue of the body portion of the patient to which a photosensitizer has been applied, the body portion of the patient being afflicted by a medical condition. The application of the treatment laser to the body portion of a patient using the painting technique treats the medical condition, reduces the symptoms associated with the medical condition, and/or alleviates the medical condition.

Abstract: An implantable emergency management drug delivery system configured to deliver a medicament to reverse the effects of a drug overdose. The implantable emergency management drug delivery system including an implantable infusion pump configured to infuse a first medicament, and an emergency handling device having at least one physiological sensor configured to monitor a condition of a patient for a possibility of an overdose from the first medicament, a communication module configured to communicate the possibility of an overdose to the implantable infusion pump, and an implantable medicament delivery mechanism configured to deliver a second medicament to reduce one or more adverse physiological effects of the first medicament.

Abstract: The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

Abstract: Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and/or orally disintegrating tablet comprising an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

Abstract: This disclosure provides pharmaceutical compositions comprising defined amino acid components, and methods for treating traumatic brain injury comprising administering an effective amount of the compositions to a subject in need thereof.

Abstract: A method for treating skin of a person is disclosed. The method can include topically applying to the skin of the person a composition comprising an effective amount of an aqueous, alcoholic, or aqueous-alcoholic extract from Vinca major, wherein the composition reduces melanin production in the skin, increases antioxidant activity in the skin, and/or increases skin moisture content.

Abstract: The present invention relates to a composite agent comprising polmacoxib and pregabalin. The present invention relates to a pharmaceutical composition and a drug or pain reliever, which each comprise the two active ingredients of polmacoxib and pregabalin and, more particularly, to a drug or pain reliever for treatment of moderately severe, acute, chronic, or neuropathic pain attributed to inflammation and various factors, an effect thereof, and a use thereof.

Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.

Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.

Abstract: Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury.

Abstract: A synergistic composition of naturally occurring active ingredients is described, which has proved particularly effective in the treatment and/or prevention of epistaxis, particularly in acute or chronic episodes of infectious and inflammatory epistaxis. The composition includes the synergistic combination of hyaluronic acid or a salt thereof, silver, vitamin B5 or pro-vitamin B5, and optionally vitamin E or an ester thereof.

Abstract: A method for treating a hyperhomocysteinemic subject having cerebral ischemic stroke generally includes administering to the hyperhomocysteinemic subject, following cerebral stroke, a composition that includes an inhibitor or an antagonist of a GluN2A-containing N-methyl-D-aspartate receptor (NMDAR) in an amount effective to ameliorate at least one symptom or clinical sign of cerebral stroke.

Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ?-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.